Top

Journal of Neurology

Published in:

01-10-2014 | Letter to the Editors

Antiphospholipid antibodies: a possible biomarker of disease activity in multiple sclerosis and neuromyelitis optica spectrum disorders

Authors: Tatiana Koudriavtseva, Domenico Plantone, Rosaria Renna

Published in: Journal of Neurology | Issue 10/2014

Excerpt

Dear Sirs, …

Iong Y, He Y, Zheng Y, Chen M, Zhang B, Gao C (2013) Serum anticardiolipin antibodies in patients with neuromyelitis optica spectrum disorder. J Neurol 260(12):3150–3157CrossRef

Wu L, Huang D, Yang Y, Wu W (2014) Combined screening for serum anti-nuclear and anti-aquaporin-4 antibodies improves diagnostic accuracy for distinguishing neuromyelitis optica from multiple sclerosis. Eur Neurol 72(1–2):103–108CrossRefPubMed

Koudriavtseva T, D’Agosto G, Mandoj C, Sperduti I, Cordiali-Fei P (2014) High frequency of antiphospholipid antibodies in relapse of multiple sclerosis: a possible indicator of inflammatory-thrombotic processes. Neurol Sci. doi:10.1007/s10072-014-1823-4

Spadaro M, Amendolea MA, Mazzucconi MG, Fantozzi R, Di Lello R, Zangari P, Masala G (1999) Autoimmunity in multiple sclerosis: study of a wide spectrum of autoantibodies. Mult Scler 5(2):121–125CrossRefPubMed

Garg N, Zivadinov R, Ramanathan M, Vasiliu I, Locke J, Watts K, Lema J, Rajeswary J, Munschauer FE, Ambrus J Jr, Weinstock-Guttman B (2007) Clinical and MRI correlates of autoreactive antibodies in multiple sclerosis patients. J Neuroimmunol 187(1–2):159–165CrossRefPubMed

Bidot CJ, Horstman LL, Jy W, Jimenez JJ, Bidot C Jr, Ahn YS, Alexander JS, Gonzalez-Toledo E, Kelley RE, Minagar A (2007) Clinical and neuroimaging correlates of antiphospholipid antibodies in multiple sclerosis: a preliminary study. BMC Neurol 7:36PubMedCentralCrossRefPubMed

Zivadinov R, Ramanathan M, Ambrus J, Hussein S, Ramasamy DP, Dwyer MG, Bergsland N, Minagar A, Weinstock-Guttman B (2012) Anti-phospholipid antibodies are associated with response to interferon-beta1a treatment in MS: results from a 3-year longitudinal study. Neurol Res 34(8):761–769. doi:10.1179/1743132812Y.0000000076 CrossRefPubMed

Brunetti A, Ricchieri GL, Patrassi GM, Girolami A, Tavolato B (1981) Rheological and fibrinolytic findings in multiple sclerosis. J Neurol Neurosurg Psychiatry 44(4):340–343PubMedCentralCrossRefPubMed

Kirichuk VF, Streknev AG (2003) The role of hemostasis system in the pathogenesis and course of multiple sclerosis. Zh Nevrol Psikhiatr Im S S Korsakova (Spec No 2):34–38

10.

Aksungar FB, Topkaya AE, Yildiz Z, Sahin S, Turk U (2008) Coagulation status and biochemical and inflammatory markers in multiple sclerosis. J Clin Neurosci 15(4):393–397. doi:10.1016/j.jocn.2007.02.090 CrossRefPubMed

11.

Campos-de-Magalhães M, de Almeida AJ, Papaiz-Alvarenga RM, Gadelha T, Morais-de-Sá CA, Alves-Leon SV (2009) Normal plasma antithrombin activity in patients with relapsing-remitting and secondary progressive multiple sclerosis. Clin Neurol Neurosurg 111(5):407–411. doi:10.1016/j.clineuro.2008.11.016 CrossRefPubMed

12.

Ingram G, Hakobyan S, Hirst CL, Harris CL, Loveless S, Mitchell JP, Pickersgill TP, Robertson NP, Morgan BP (2012) Systemic complement profiling in multiple sclerosis as a biomarker of disease state. Mult Scler 18(10):1401–1411PubMedCentralCrossRefPubMed

13.

Festoff BW, Li C, Woodhams B, Lynch S (2012) Soluble thrombomodulin levels in plasma of multiple sclerosis patients and their implication. J Neurol Sci 323(1–2):61–65. doi:10.1016/j.jns.2012.08.008 CrossRefPubMed

14.

Koudriavtseva T (2014) Thrombotic processes in multiple sclerosis as manifestation of innate immune activation. Front Neurol 5:119. doi:10.3389/fneur.2014.00119 PubMedCentralCrossRefPubMed

15.

Renaud M, Aupy J, Uring-Lambert B, Chanson JB, Collongues N, Blanc F, De Sèze J (2014) Isolated anti-β2-glycoprotein I antibodies in neurology: a frontier syndrome between multiple sclerosis and antiphospholipid syndrome? Eur J Neurol 21(6):901–906. doi:10.1111/ene.12408 CrossRefPubMed

16.

Sastre-Garriga Reverter JC, Font J, Tintoré M, Espinosa G, Montalban X (2001) Anticardiolipin antibodies are not a useful screening tool in a nonselected large group of patients with multiple sclerosis. Ann Neurol 49(3):408–411CrossRefPubMed

Title: Antiphospholipid antibodies: a possible biomarker of disease activity in multiple sclerosis and neuromyelitis optica spectrum disorders
Authors: Tatiana Koudriavtseva
Domenico Plantone
Rosaria Renna
Publication date: 01-10-2014
Publisher: Springer Berlin Heidelberg
Published in: Journal of Neurology / Issue 10/2014
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-014-7506-5

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Antiphospholipid antibodies: a possible biomarker of disease activity in multiple sclerosis and neuromyelitis optica spectrum disorders

Excerpt

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 10/2014

Prior medical conditions and the risk of amyotrophic lateral sclerosis

Severe familial paroxysmal exercise-induced dyskinesia

Recent advances in the neuroimmunology of cell-surface CNS autoantibody syndromes, Alzheimer’s disease, traumatic brain injury and schizophrenia

Transdermal rotigotine in advanced Parkinson’s disease: a randomized, double-blind, placebo-controlled trial

Gadolinium enhancement patterns of tumefactive demyelinating lesions: correlations with brain biopsy findings and pathophysiology

Atrophy of the cholinergic basal forebrain in dementia with Lewy bodies and Alzheimer’s disease dementia